Results 241 to 250 of about 37,314 (262)

Characteristics and outcome for heart failure patients with mid-range ejection fraction

Journal of Cardiovascular Medicine, 2018
Aims The aim of this study was to compare precipitants, presenting symptoms and outcomes of patients with heart failure and mid-range ejection fraction (HFmrEF), heart failure and preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in an Australian cohort.
Nelson, Wang, Susan, Hales, Edward, Barin, Geoffrey, Tofler   +3 more
openaire   +2 more sources

[Heart failure with "mid-range" ejection fraction: a new clinical entity?]

Therapeutische Umschau. Revue therapeutique, 2018
Heart failure with "mid-range" ejection fraction: a new clinical entity? Abstract. The new entity of heart failure with mid-range ejection fraction (HFmrEF) is defined as clinical syndrome characterized by typical symptoms and signs of heart failure (HF), an EF of 40 - 49 %, elevated natriuretic peptides and documentation of structural heart disease ...
openaire   +2 more sources

[Heart failure with mid-range ejection fraction. Looking for Middle Earth?]

Giornale italiano di cardiologia (2006), 2019
The latest guidelines of the European Society of Cardiology have proposed a classification of heart failure based on left ventricular ejection fraction. Three distinct groups have been identified: heart failure with ejection fraction ≥50%, between 40 and 49%, and
Donato, Mele, Giovanni Andrea, Luisi, Marianna, Nardozza, Roberto, Ferrari   +3 more
openaire   +1 more source

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

New England Journal of Medicine, 2021
Stefan D Anker, Javed Butler, Gerasimos Filippatos   +2 more
exaly  

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Nature Medicine, 2022
Stefan D Anker, Javed Butler, João Pedro Ferreira   +2 more
exaly  

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Lancet, The, 2022
Sanjiv J Shah, Barry A Borlaug, Donald E Cutlip   +2 more
exaly  

Heart Failure With “Mid-Range” Ejection Fraction—New Opportunities

Journal of Cardiac Failure, 2016
openaire   +2 more sources

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Nature Medicine, 2022
Pardeep S Jhund, Toru Kondo, Jawad Haider Butt   +2 more
exaly  

Heart Failure With Mid-Range Ejection Fraction – The “Middle” Child of the Heart Failure Siblings

The American Journal of the Medical Sciences, 2020
Atanda, Adebayo, Gurusher, Panjrath
openaire   +2 more sources

Demystifying Heart Failure with Mid-Range Ejection Fraction Using Machine Learning

2021 Computing in Cardiology (CinC), 2021
Achal Dixit, Soumi Chattopadhyay
openaire   +1 more source